Nitrosamine impurity in ranitidine

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2019年 / 1772卷 / 1期

关键词：

D O I：

10.1007/s40278-019-68130-0

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：3 / 3

相关论文

共 50 条

[1] Nitrosamine impurity detected in sitagliptin
Reactions Weekly, 2022, 1920 (1) : 3 - 3
[2] Sitagliptin may be contaminated with nitrosamine impurity
Reactions Weekly, 2022, 1925 (1) : 5 - 5
[3] Atomoxetine recalled due to nitrosamine impurity
Reactions Weekly, 2025, 2047 (1) : 1 - 1
[4] A Review on N-nitrosamine Impurity
Pal, Debangana
Babu, B.
CURRENT PHARMACEUTICAL ANALYSIS, 2024, 20 (01) : 2 - 11
[5] New nitrosamine impurity detected in losartan tablets
Reactions Weekly, 2019, 1744 (1) : 5 - 5
[6] Nitrosamine impurity risk assessment required in medicine registration applications
Reactions Weekly, 2023, 1966 (1) : 4 - 4
[7] Pfizer Australia recalls batches of varenicline due to nitrosamine impurity
Reactions Weekly, 2021, 1869 (1) : 4 - 4
[8] How to comply with FDA-imposed nitrosamine impurity testing
Walker, Michael
Manufacturing Chemist, 2020, 91 (06): : 32 - 34
[9] Impurity Testing of Ranitidine Products: US FDA Update
不详
PHARMACEUTICAL MEDICINE, 2020, 34 (01) : 70 - 70
[10] Ascend recalls dabigatran etexilate capsules due to nitrosamine impurity
Reactions Weekly, 2023, 1951 (1) : 1 - 1

← 1 2 3 4 5 →